Brognard John, Niederst Matthew, Reyes Gloria, Warfel Noel, Newton Alexandra C
Department of Pharmacology and Biomedical Sciences Graduate Program, University of California at San Diego, La Jolla, California 92093-0721, USA.
J Biol Chem. 2009 May 29;284(22):15215-23. doi: 10.1074/jbc.M901468200. Epub 2009 Mar 26.
PHLPP2 (PH domain leucine-rich repeat protein phosphatase 2) terminates Akt and protein kinase C (PKC) activity by specifically dephosphorylating these kinases at a key regulatory site, the hydrophobic motif (Ser-473 in Akt1). Here we identify a polymorphism that results in an amino acid change from a Leu to Ser at codon 1016 in the phosphatase domain of PHLPP2, which reduces phosphatase activity toward Akt both in vitro and in cells, in turn resulting in reduced apoptosis. Depletion of endogenous PHLPP2 variants in breast cancer cells revealed the Ser-1016 variant is less functional toward both Akt and PKC. In pair-matched high grade breast cancer samples we observed retention of only the Ser allele from heterozygous patients (identical results were observed in a pair-matched normal and tumor cell line). Thus, we have identified a functional polymorphism that impairs the activity of PHLPP2 and correlates with elevated Akt phosphorylation and increased PKC levels.
PHLPP2(含PH结构域富含亮氨酸重复序列蛋白磷酸酶2)通过在关键调控位点——疏水基序(Akt1中的Ser-473)特异性地使这些激酶去磷酸化,从而终止Akt和蛋白激酶C(PKC)的活性。在此,我们鉴定出一种多态性,该多态性导致PHLPP2磷酸酶结构域第1016位密码子处的氨基酸由亮氨酸变为丝氨酸,这在体外和细胞内均降低了对Akt的磷酸酶活性,进而导致细胞凋亡减少。乳腺癌细胞中内源性PHLPP2变体的缺失表明,Ser-1016变体对Akt和PKC的功能均较弱。在配对的高级别乳腺癌样本中,我们观察到杂合患者仅保留了Ser等位基因(在配对的正常和肿瘤细胞系中观察到相同结果)。因此,我们鉴定出一种功能性多态性,它损害了PHLPP2的活性,并与Akt磷酸化升高和PKC水平增加相关。